Small Molecule Tyrosine Kinase Inhibitor Market
Global Small Molecule Tyrosine Kinase Inhibitor Market Size, Share, and Trend Analysis Report, By Type (Phase-I, Phase-I/II, Phase-II, Phase-II/III, and Phase-III), By Application (Lung Cancer, Breast Cancer, and Others), Forecast (2022-2028)
The global small molecule tyrosine kinase inhibitor market is expected to grow at a significant CAGR (2022-2028). TKIs (tyrosine kinase inhibitors) are small molecules that block intracellular signalling pathways in tumor cells, causing deregulation of key cell functions such as proliferation and differentiation. Furthermore, small molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy, according to the National Center for Biotechnology Information (NCBI). The increasing prevalence of cancer around the world is a major factor driving market growth. Furthermore, product innovation with the small molecule tyrosine kinase inhibitors for treating multiple conditions is expected to drive the market growth. For instance, in July 2021, Ocular Therapeutix, Inc. dosed the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (wet AMD). Thus, the ongoing clinical trial process in the concerned market will spur the global market growth.
Impact of COVID-19 Pandemic on Global Small Molecule Tyrosine Kinase Inhibitor Market
The COVID-19 pandemic had impacted the global small molecule tyrosine kinase inhibitor industry significantly owning to the lockdown in most of the nations to control the spread of the virus. In 2021, the Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study reported that 356 centers from 54 countries across six continents participated between April 21 and May 8, 2021. Every year, 716,979 new cancer patients are treated at these facilities. During the pandemic, the majority of them (88.2 %) reported difficulties in providing care. Although 55.3% cut services as part of a preventive strategy, other common reasons included an overburdened system (19.9%), a lack of personal protective equipment (19.1%), a staff shortage (17.9%), and limited access to medications (9.8%).
Segmental Outlook
The global small molecule tyrosine kinase inhibitor market is segmented based on type and application.Based on the type, the market is segmented into phase1, phase1/2, phase2, phase2/3, phase3. Based on the application, the market is sub-segmented into the lung cancer, breast cancer, and other. Based on application, the market is sub-segmented into the lung cancer, breast cancer is expected to hold major share in the market.
Global Small Molecule Tyrosine Kinase Inhibitor MarketShare by Application, 2021 (%)
Breast Cancer Segment Holds the Major Share in the Global Small Molecule Tyrosine Kinase Inhibitor Market
The high prevalence of breast cancer compared to lung cancer and high suitability of small molecule tyrosine kinase inhibitors in its treatment is a key factor driving the growth of this market segment. According to the WHO, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 mortalities occurred globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer. There are more lost disability-adjusted life years (DALYs) by women to breast cancer globally than any other type of cancer. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life. Therefore, the high demand small molecule tyrosine kinase inhibitor for its treatment is anticipated to drive the growth of this market segment.
Regional Outlooks
The global small molecule tyrosine kinase inhibitor market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). Among the regions, the North America is anticipated to hold a significant share in the market
Global Small Molecule Tyrosine Kinase Inhibitor Market Growth, by Region 2022-2028
North America Expected to Hold Considerable Share in the Global Small Molecule Tyrosine Kinase Inhibitor Market
The North American countries including the US and Canada have a developed and well-structured healthcare system which is a key promoter for the growth of the global small molecule tyrosine kinase inhibitor market. These systems also encourage R&D, especially on Cancer. Along with these systems several companies in these countries have been involved in cancer research. These policies have encouraged other global players to enter the US and Canada; which in turn driving the market growth. Moreover, the high prevalence of lethal disorder such as cancer across the region is further aiding to the market demand. Prevalence of cancer in the US is one of the highest across the globe. TKIs are used to treat cancer, therefore growing prevalence of cancer will positively impact the market growth. According to American Cancer Society, Inc. in 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the US, thus, driving the small molecule TKI market during the forecast period.
Market Players Outlook
The major companies serving the global small molecule tyrosine kinase inhibitor market include Merck & Co., Novartis, Pfizer, Sanofi, GlaxoSmithKline, Biogen Idec, Bayer Healthcare Pharmaceuticals, Johnson & Johnson, Tolero Pharmaceutical. For instance, Seattle Genetics granted Merck an exclusive license to market TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, in Asia, the Middle East, and Latin America, as well as other non-US, Canada, and European regions, in September 2021. TUKYSA is a drug that is used to treat cancers that have HER2 mutations.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global small molecule tyrosine kinase inhibitor market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Small Molecule Tyrosine Kinase Inhibitor Market
• Recovery Scenario of Global Small Molecule Tyrosine Kinase Inhibitor Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Novartis AG
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Pfizer Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Sanofi SA
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. GlaxoSmithKline Plc
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Biogen Idec
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Small Molecule Tyrosine Kinase Inhibitor Market by Type
4.1.1 Phase1
4.1.2 Phase1/2
4.1.3 Phase2
4.1.4 Phase2/3
4.1.5 Phase3
4.2. By Application
4.2.1 Lung cancer
4.2.2 Breast cancer
4.2.3 Others
5 Regional Analysis
5.2 North America
5.2.1 US
5.2.2 Canada
5.3 Europe
5.3.1 UK
5.3.2 Germany
5.3.3 Italy
5.3.4 Spain
5.3.5 France
5.3.6 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 India
5.4.3 Japan
5.4.4 South Korea
5.4.5 Rest of Asia-Pacific
5.5 Rest of the World
6 Company Profiles
6.1. Merck Group
6.2. Novartis AG
6.3. Pfizer Inc.
6.4. Sanofi SA
6.5. GlaxoSmithKline PLC
6.6. Biogen Idec
6.7. Bayer Healthcare Pharmaceuticals
6.8. Johnson & Johnson, Inc.
6.9. Tolero Pharmaceutical
**List not Exhaustive
1. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL PHASE 1 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL PHASE ½ SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL PHASE 2 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL PHASE 2/3 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL PHASE 3 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
8. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR FOR LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR FOR BREAST CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR FOR OTHER DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
15. EUROPEAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. REST OF THE WORLD SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLON)
1. IMPACT OF COVID-19 ON GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET, 2022-2028 (%)
4. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL PHASE 1 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL PHASE 1/2 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL PHASE 2 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL PHASE 2/3 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL PHASE 3 SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
11. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR FOR LUNG CANCER TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR FOR OTHER DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR FOR BREAST CANCER TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
17. UK SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD SMALL MOLECULE TYROSINE KINASE INHIBITOR MARKET SIZE, 2021-2028 ($ MILLION)
